BUB1缺乏抑制脏清细胞癌通过PI3K/Akt途径进展:一个以生物信息学为导向的验证研究
Xiaolin Zi1, Jinpeng Ma2, Xiaoxia Li3
1Department of Medical Oncology, Fourth Hospital of Harbin Medical University, Yiyuan Street No. 37, Nangang District, Harbin, 150001, China.
在脏清细胞癌 (KIRC) 中,BUB1基因升高,促进瘤生长. 沉默BUB1通过禁用PI3K/Akt路径来抑制KIRC的进展,这表明BUB1是潜在的诊断和治疗目标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 脏清细胞癌 (KIRC) 缺乏完全理解的分子机制,限制了治疗进展.
- 识别新的分子标对于改善KIRC诊断,治疗和预后至关重要.
研究的目的:
- 研究BUB1基因在KIRC进展中的作用.
- 探索BUB1作为KIRC的潜在生物标志物和治疗点.
主要方法:
- 对UCSC数据库数据集的生物信息分析.
- 在体外和体外功能丧失实验 (BUB1敲击).
- PI3K/Akt路径分析和操纵.
主要成果:
- 在KIRC组织和细胞中,BUB1基因表达显著升高,与预后不佳相关.
- 在BUB1的淘汰中,它抑制了KIRC细胞的增殖,迁移,上皮-介质细胞转换 (EMT) 和瘤生长,同时诱导了亡.
- 沉默BUB1会使PI3K/Akt通路失活,而这种效果在PI3K/Akt通路激活器中是可逆的.
结论:
- 通过PI3K/Akt信号通路,BUB1促进KIRC的进展.
- BUB1是KIRC诊断的潜在生物标志物,也是KIRC治疗的治疗点.
更多相关视频
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
相关概念视频
Inhibition of Cdk Activity
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
